Spots Global Cancer Trial Database for The Roles of Age, Comorbidity, and Telomere Length in Lung Cancer Treatment and Prognosis

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: The Roles of Age, Comorbidity, and Telomere Length in Lung Cancer Treatment and Prognosis

Official Title: The Roles of Age, Comorbidity, and Telomere Length in Lung Cancer Treatment and Prognosis

Study ID: NCT01963533

Conditions

Lung Cancer

Interventions

Study Description

Brief Summary: The investigators hypothesize that the age-adjusted telomere length in lung cancer patients before chemotherapy may be correlated to comorbidity status and predict outcome. The change of telomere length shortening after chemotherapy may relate to treatment side effect and treatment response.

Detailed Description: Except chemotherapy, telomere shortening were also related to a variety of cellular stress, including hydrogen peroxide, UV, and x-irradiation, transforming growth factor-beta, overexpression of oncogenes such as Ha-Ras. The cellular stress induced telomere shortening and/or telomere dysfunction and promote accelerated senescence in normal and malignant cells. Oxidative stress, which presented in several chronic inflammatory diseases, such as atherosclerosis, coronary artery disease, and chronic obstructive airway disease, was also found to be correlated with telomere shortening.